A Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Filgotinib, With Single Arm Induction and Maintenance, in Pediatric Subjects (8 to <18 Years of Age) With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 08 Feb 2026
At a glance
- Drugs Filgotinib (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms Galapeduca
- Sponsors Alfasigma
Most Recent Events
- 10 Dec 2025 Planned primary completion date changed from 1 Jun 2027 to 1 Jun 2028.
- 10 Dec 2025 Status changed from not yet recruiting to recruiting.
- 14 Aug 2025 Planned initiation date changed from 1 Jul 2025 to 1 Sep 2025.